factor (premature birth, health care worker mother, day care attendance, or prior antibiotic exposure). Most received ceftriaxone empirically in the ED, followed by an intramuscular (i.m.) or oral (p.o.) ␤-lactam agent. Patient 2, who responded well clinically to oral trimethoprim-sulfamethoxazole after a single ceftriaxone dose, returned 1 month later for a new (different strain) episode and received one dose of ceftriaxone for 5 days. Telephone follow-up confirmed, for all 8 episodes, no further symptoms after the initial ED visit and subsequent therapy, despite uniform in vitro resistance to ceftriaxone (MICs, all at Ն16 g/ml) and, for the trimethoprim-sulfamethoxazole-treated episode, trimethoprim-sulfamethoxazole.
Enterobacteriaceae producing CTX-M enzymes, especially in community-onset infection, are an emerging public health threat (7, 8) . Here we document community-associated urinary tract infections among U.S. children, predominantly due to CTX-M-15-producing E. coli, and describe the organisms, which resemble CTX-M-15-producing E. coli from adults, including the presence of the epidemic ST131 clonal group (5), extensive virulence genotypes, and coresistance to fluoroquinolones (75%) and trimethoprim-sulfamethoxazole (25%).
Notably, only 4 children exhibited established ESBL-associated risk factors (1) . Accordingly, to ensure appropriate empirical therapy, ED physicians may need to consider the possibility of community-acquired ESBLs, even in pediatric patients who lack identifiable risk factors, especially in high-prevalence locales for ESBL-producing E. coli (11, 12) .
Isolates 2a and 2b, recovered 1 month apart from the same patient, exhibited distinct PFGE profiles and gentamicin phenotypes, indicating reinfection with a different CTX-M-15-positive strain. This patient's ESBL-associated risk factor was her health care worker mother, a scenario suggesting possible repeated introduction of diverse health care-associated, ESBL-producing E. coli strains into the household from the mother's workplace (4, 8) . These 7 children all did well. However, the unfavorable international experience with invasive pediatric ESBL-positive enterobacterial infections, including neonatal meningitis and bacteremia (2, 9) , urges heightened vigilance and provision of appropriately targeted antimicrobial therapy, now that virulent-appearing, ESBLproducing E. coli strains are present among community-dwelling pediatric patients in the United States.
